0 Maoni
0 Shiriki
469 Mitazamo
0 Hakiki
Tafuta
Gundua watu wapya, unda miunganisho mipya na upate marafiki wapya
-
Tafadhali ingia kwenye akaunti ili kupenda, kushiriki na kutoa maoni!
-
Carfilzomib Market Expands with 7.5% CAGR Driven by Advances in Multiple Myeloma TherapiesAccording to a new report from Intel Market Research, the global Carfilzomib market was valued at USD 1.45 billion in 2025 and is projected to reach USD 2.89 billion by 2034, growing at a steady CAGR of 7.5% during the forecast period (2025–2034). This growth reflects the expanding clinical application of Carfilzomib in treating relapsed/refractory multiple myeloma, coupled with rising...0 Maoni 0 Shiriki 324 Mitazamo 0 Hakiki
-
Global BRAF Kinase Inhibitors Market to Reach USD 3.78 Billion by 2034 Amid Rising Precision Oncology AdoptionAccording to a new report from Intel Market Research, the global BRAF kinase inhibitors market was valued at USD 1.85 billion in 2025 and is projected to reach USD 3.78 billion by 2034, growing at a CAGR of 7.5% during the forecast period (2026–2034). This growth trajectory reflects the expanding applications of BRAF inhibitors in precision oncology and the increasing prevalence of...0 Maoni 0 Shiriki 270 Mitazamo 0 Hakiki
-
How are new therapies reshaping the urothelial cancer drugs market?Competitive Analysis of Executive Summary Urothelial Cancer Drugs Market Size and Share CAGR Value The global Urothelial Cancer Drugs market size was valued at USD 1.44 billion in 2024 and is expected to reach USD 2.80 billion by 2032, at a CAGR of 8.7% during the forecast period Keeping into consideration the customer requirement, an influential Urothelial Cancer Drugs...0 Maoni 0 Shiriki 527 Mitazamo 0 Hakiki
-
VEGF Inhibitors for Cancer Market Growing at 7.3% CAGR Amid Rising Targeted Oncology TherapiesAccording to a new report from Intel Market Research, the global VEGF Inhibitors for Cancer market was valued at USD 8.42 billion in 2025 and is projected to reach USD 15.67 billion by 2034, growing at a CAGR of 7.3% during the forecast period (2026–2034). This growth trajectory reflects the increasing adoption of targeted therapies in oncology and significant advancements in angiogenesis...0 Maoni 0 Shiriki 284 Mitazamo 0 Hakiki
-
VEGF Inhibitors for Cancer Market Growing at 7.3% CAGR Amid Rising Targeted Oncology TherapiesAccording to a new report from Intel Market Research, the global VEGF Inhibitors for Cancer market was valued at USD 8.42 billion in 2025 and is projected to reach USD 15.67 billion by 2034, growing at a CAGR of 7.3% during the forecast period (2026–2034). This growth trajectory reflects the increasing adoption of targeted therapies in oncology and significant advancements in angiogenesis...0 Maoni 0 Shiriki 245 Mitazamo 0 Hakiki
-
What advancements are shaping the Waldenstrom’s macroglobulinemia treatment market?Key Drivers Impacting Executive Summary Waldenstrom’s Macroglobulinemia (WM) Treatment Market Size and Share CAGR Value The Global Waldenstrom’s Macroglobulinemia (WM) Treatment Market size was valued at USD 160.50 million in 2024 and is expected to reach USD 228.70 million by 2032, at a CAGR of 5.20% during the forecast period Analysis and discussion of important...0 Maoni 0 Shiriki 424 Mitazamo 0 Hakiki
-
What breakthroughs are propelling the thyroid cancer drug market forward?Executive Summary Thyroid Cancer Drug Market Value, Size, Share and Projections CAGR Value Data Bridge Market Research analyses that the global thyroid cancer drug market which was USD 712.56 million in 2022, is expected to reach USD 2,505.56 million by 2030, and is expected to undergo a CAGR of 17.2% during the forecast period 2023-2030. The world class Thyroid Cancer Drug...0 Maoni 0 Shiriki 494 Mitazamo 0 Hakiki
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
